Jazz Q2 FY26 GAAP EPS rises 16% to $2.78; revenue increases 16% to $1.21 billion

• Jazz Pharmaceuticals posted 2Q26 revenue of $1.21 billion, up 16% year over year, as GAAP net income swung to $192.8 million.
• GAAP diluted EPS was $2.78; non-GAAP adjusted EPS was $5.71.
• Xywav revenue rose 13% to $471.2 million; Epidiolex/Epidyolex climbed 16% to $292.1 million.
• Zepzelca revenue increased 42% to $105.8 million; Modeyso delivered $48.2 million in revenue.
• 2026 revenue guidance was raised to $4.6 billion-$4.75 billion from $4.25 billion-$4.5 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jazz Pharmaceuticals plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608031605PR_NEWS_USPR_____SF17345) on August 03, 2026, and is solely responsible for the information contained therein.